Comirnaty (tozinameran - Pfizer/BIONTECH) - versus control - for COVID-19 prophylaxis (children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

confirmed Covid-19, from 1st dose 0.08 [0.02, 0.34]< 10%1 study (1/-)100.0 %NAnot evaluable crucial-
symptomatic Covid-19 0.03 [0.00, 0.50]< 10%1 study (1/-)99.2 %NAnot evaluable important-
vaccine efficacy after dose 1 (and before dose 2) 0.25 [0.05, 1.13]< 10%1 study (1/-)96.4 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.